---
title: "301333.SZ (301333.SZ) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/301333.SZ/news.md"
symbol: "301333.SZ"
name: "301333.SZ"
parent: "https://longbridge.com/zh-HK/quote/301333.SZ.md"
datetime: "2026-03-13T11:02:44.400Z"
locales:
  - [en](https://longbridge.com/en/quote/301333.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301333.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301333.SZ/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/301333.SZ/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/301333.SZ/news.md)


# 301333.SZ (301333.SZ) — 相關新聞

### [Several shareholders of R&G Pharma plan to reduce their holdings by no more than 1.9193 million shares](https://longbridge.com/zh-HK/news/277631334.md)
*2026-03-03T13:38:04.000Z*
> R&G Pharma announced that shareholders Ningbo Kangyunfu Equity Investment Co., Ltd., Ningbo Ruiguang Venture Capital Par

### [CSPC Innovation: Net profit of 190 million yuan in 2025, a year-on-year increase of 7.75%](https://longbridge.com/zh-HK/news/277002968.md)
*2026-02-26T08:05:44.000Z*
> CSPC Innovation released its performance preliminary report for 2025, with operating revenue of 7.5 billion yuan, a year

### [Aozhe Xu Pingjun: The implementation of enterprise-level AI is not just about technology | Chuang·Wen](https://longbridge.com/zh-HK/news/275460354.md)
*2026-02-10T12:38:14.000Z*
> Xujingjun, founder and CEO of Aozhe, discussed the challenges of implementing enterprise-level AI in a podcast by Huachu

### [](https://longbridge.com/zh-HK/news/275395594.md)
*2026-02-10T03:09:38.000Z*
> The North Exchange 50 has fallen by 1.01% within the day. Among the constituent stocks, Naconor has dropped by 4.38%, Ge

### [](https://longbridge.com/zh-HK/news/274591849.md)
*2026-02-03T03:23:13.000Z*
> The North Exchange 50 has increased by 2.10% within 50 days. Among the constituent stocks, Liancheng CNC rose by 14.07%,

### [](https://longbridge.com/zh-HK/news/274536080.md)
*2026-02-02T15:46:04.000Z*
> Novo Nordisk: CagriSema shows superior weight loss effects compared to semaglutide

### [](https://longbridge.com/zh-HK/news/274536017.md)
*2026-02-02T15:45:59.000Z*
> Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect 

### [Novo Nordisk's Wegovy oral tablet weekly prescription volume exceeds 26,000](https://longbridge.com/zh-HK/news/274447445.md)
*2026-02-02T01:53:52.000Z*
> Barclays analysts cited data from IQVIA, indicating that the prescription volume for Novo Nordisk's Wegovy tablets reach

### [Zhitong A-share lock-up release overview | February 2](https://longbridge.com/zh-HK/news/274442024.md)
*2026-02-02T01:01:05.000Z*
> On February 2nd, a total of 7 listed companies will have their restricted shares unlocked, with a total market value of